Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Status:
Terminated
Trial end date:
2020-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be
dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster)
along with standard anticoagulant therapy as compared to the standard of care anticoagulant
therapy alone.